Table 3.
Prognostic factors of completion of therapy
| N | Odds ratio (95 % CI) | p value | |
|---|---|---|---|
| Univariate analyses | |||
| Weight | 71 | 1.00 (0.96, 1.04) | 0.93 |
| Height | 71 | 0.96 (0.89, 1.04) | 0.30 |
| BSA | 71 | 0.78 (0.05, 12.51) | 0.86 |
| Duration of bone metastases | 70 | 1.00 (0.98, 1.03) | 0.84 |
| PTH | 71 | 0.95 (0.89, 1.02) | 0.17 |
| Vitamin D (/10 units) | 71 | 1.20 (1.03, 1.39) | 0.017 |
| FACT-BP Subscale | 71 | 1.01 (0.96, 1.05) | 0.82 |
| Baseline CTx (/10 units) | 71 | 0.96 (0.93, 0.99) | 0.007 |
| BSAP | 70 | 0.88 (0.77, 1.01) | 0.066 |
| NTx (/100 units) | 63 | 0.62 (0.42, 0.92) | 0.017 |
| P1NP (/1,000 units) | 63 | 0.99 (0.97, 1.01) | 0.41 |
| BSP (/10 units) | 63 | 0.86 (0.77, 0.95) | 0.003 |
| TGF-β | 63 | 1.04 (0.95, 1.14) | 0.43 |
| Activin A (/100 units) | 63 | 0.96 (0.91, 1.02) | 0.19 |
| BPI-severity | 70 | 1.00 (0.92, 1.09) | 0.93 |
| BPI-interference | 69 | 1.02 (0.97, 1.06) | 0.44 |
| Metastatic disease (bone only vs bone plus other) | 65 | 1.51 (0.56, 4.06) | 0.41 |
| Multivariate analyses | |||
| BSP (/10 units) | 63 | 0.82 (0.72, 0.93) | 0.003 |
| NTx (/100 units) | 63 | 0.62 (0.39, 0.97) | 0.035 |
| Vitamin D (/10 units) | 63 | 1.27 (1.04, 1.54) | 0.017 |
In univariate analyses, vitamin D, CTx, NTx and BSP were all statistically significant for completion of therapy. In the multivariate analyses, BSP, NTx and Vitamin D all remained statistically significant prognostic factors of completion of therapy